X4 Pharmaceuticals Inc (XFOR) - Total Assets
Based on the latest financial reports, X4 Pharmaceuticals Inc (XFOR) holds total assets worth $163.56 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See XFOR book value for net asset value and shareholders' equity analysis.
X4 Pharmaceuticals Inc - Total Assets Trend (2015–2024)
This chart illustrates how X4 Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data.
X4 Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
X4 Pharmaceuticals Inc's total assets of $163.56 Million consist of 76.6% current assets and 23.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 38.0% |
| Accounts Receivable | $1.71 Million | 1.2% |
| Inventory | $2.82 Million | 1.9% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $10.00 Million | 6.8% |
| Goodwill | $17.35 Million | 11.9% |
Asset Composition Trend (2015–2024)
This chart illustrates how X4 Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see XFOR market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: X4 Pharmaceuticals Inc's current assets represent 76.6% of total assets in 2024, a decrease from 88.2% in 2015.
- Cash Position: Cash and equivalents constituted 38.0% of total assets in 2024, down from 71.1% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 17.0% of total assets, an increase from 0.0% in 2015.
- Asset Diversification: The largest asset category is goodwill at 11.9% of total assets.
X4 Pharmaceuticals Inc Competitors by Total Assets
Key competitors of X4 Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
X4 Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.65 | 4.89 | 6.97 |
| Quick Ratio | 5.48 | 4.80 | 6.97 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $109.30 Million | $113.71 Million | $71.36 Million |
X4 Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between X4 Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.85 |
| Latest Market Cap to Assets Ratio | 2.04 |
| Asset Growth Rate (YoY) | -0.6% |
| Total Assets | $146.45 Million |
| Market Capitalization | $298.16 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values X4 Pharmaceuticals Inc's assets at a significant premium (2.04x), suggesting investors see substantial growth potential or unique competitive advantages.
Slight Asset Contraction: X4 Pharmaceuticals Inc's assets decreased by 0.6% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for X4 Pharmaceuticals Inc (2015–2024)
The table below shows the annual total assets of X4 Pharmaceuticals Inc from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $146.45 Million | -0.55% |
| 2023-12-31 | $147.26 Million | -5.35% |
| 2022-12-31 | $155.59 Million | +32.78% |
| 2021-12-31 | $117.18 Million | -4.63% |
| 2020-12-31 | $122.87 Million | -23.54% |
| 2019-12-31 | $160.70 Million | +346.33% |
| 2018-12-31 | $36.00 Million | -55.69% |
| 2017-12-31 | $81.25 Million | +968.57% |
| 2016-12-31 | $7.60 Million | -20.04% |
| 2015-12-31 | $9.51 Million | -- |
About X4 Pharmaceuticals Inc
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally bioavailable selective antagonist of chemokine receptor C-X-C chemokine receptor type 4 (CXCR4) for the treatment of patients with warts, hypogammaglobulinemia, infections, an… Read more